METTL3 Acetylation Impedes Cancer Metastasis Via Fine-Tuning Its Nuclear and Cytosolic Functions
Yuanpei Li,Xiaoniu He,Xiao Lu,Zhicheng Gong,Qing Li,Lei Zhang,Ronghui Yang,Chengyi Wu,Jialiang Huang,Jiancheng Ding,Yaohui He,Wen Liu,Ceshi Chen,Bin Cao,Dawang Zhou,Yufeng Shi,Juxiang Chen,Chuangui Wang,Shengping Zhang,Jian Zhang,Jing Ye,Han You
DOI: https://doi.org/10.1038/s41467-022-34209-5
IF: 16.6
2022-01-01
Nature Communications
Abstract:The methyltransferase like 3 (METTL3) has been generally recognized as a nuclear protein bearing oncogenic properties. We find predominantly cytoplasmic METTL3 expression inversely correlates with node metastasis in human cancers. It remains unclear if nuclear METTL3 is functionally distinct from cytosolic METTL3 in driving tumorigenesis and, if any, how tumor cells sense oncogenic insults to coordinate METTL3 functions within these intracellular compartments. Here, we report an acetylation-dependent regulation of METTL3 localization that impacts on metastatic dissemination. We identify an IL-6-dependent positive feedback axis to facilitate nuclear METTL3 functions, eliciting breast cancer metastasis. IL-6, whose mRNA transcript is subjected to METTL3-mediated m6A modification, promotes METTL3 deacetylation and nuclear translocation, thereby inducing global m6A abundance. This deacetylation-mediated nuclear shift of METTL3 can be counterbalanced by SIRT1 inhibition, a process that is further enforced by aspirin treatment, leading to ablated lung metastasis via impaired m6A methylation. Intriguingly, acetylation-mimetic METTL3 mutant reconstitution results in enhanced translation and compromised metastatic potential. Our study identifies an acetylation-dependent regulatory mechanism determining the subcellular localization of METTL3, which may provide mechanistic clues for developing therapeutic strategies to combat breast cancer metastasis.